The recent release of best practice guidance on patient information leaflets establishes a comprehensive legal framework in accordance with EU and national legislation. This guidance emphasizes the importance of effective information design, ensuring that patient leaflets are not only compliant but also user-friendly and informative.
As the pharmaceutical industry continues to prioritize patient engagement and safety, the implications of this guidance are significant. Regulatory, QA/QC, and CMC professionals must now navigate these updated standards to enhance the clarity and accessibility of patient information. This will likely lead to improved patient understanding and adherence to medication regimens, ultimately contributing to better health outcomes.
For sourcing and portfolio management teams, the guidance may necessitate a reevaluation of existing patient information materials, aligning them with the latest best practices. Adopting these recommendations is essential for companies aiming to maintain compliance while fostering trust and transparency with their patients.
Use the database as your supply chain compass →
